Nevro Corp. (NYSE:NVRO) Stake Raised by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in shares of Nevro Corp. (NYSE:NVRO) by 3.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 314,481 shares of the medical equipment provider’s stock after acquiring an additional 10,806 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.84% of Nevro worth $1,170,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of NVRO. Western Standard LLC acquired a new position in shares of Nevro in the third quarter worth $5,473,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Nevro by 130.7% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,000,000 shares of the medical equipment provider’s stock worth $5,590,000 after purchasing an additional 566,462 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Nevro by 50.8% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 732,717 shares of the medical equipment provider’s stock worth $4,096,000 after purchasing an additional 246,979 shares in the last quarter. ArrowMark Colorado Holdings LLC lifted its holdings in shares of Nevro by 2.4% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 4,391,258 shares of the medical equipment provider’s stock valued at $24,547,000 after buying an additional 102,150 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Nevro by 171.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 135,145 shares of the medical equipment provider’s stock valued at $755,000 after buying an additional 85,324 shares during the last quarter. Hedge funds and other institutional investors own 95.52% of the company’s stock.

Nevro Stock Performance

Shares of NYSE:NVRO opened at $5.85 on Monday. The business has a fifty day moving average of $5.56 and a 200-day moving average of $4.96. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.76 and a current ratio of 5.02. Nevro Corp. has a twelve month low of $3.17 and a twelve month high of $14.43. The firm has a market cap of $224.28 million, a PE ratio of -3.09 and a beta of 0.94.

Nevro (NYSE:NVRO) last announced its quarterly earnings data on Tuesday, March 4th. The medical equipment provider reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.15. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. The firm had revenue of $105.55 million during the quarter, compared to analyst estimates of $102.61 million. On average, equities research analysts predict that Nevro Corp. will post -2.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Jefferies Financial Group upgraded Nevro from an “underperform” rating to a “hold” rating and increased their price objective for the stock from $4.50 to $5.85 in a report on Monday, February 10th. Wells Fargo & Company dropped their price target on shares of Nevro from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. StockNews.com started coverage on shares of Nevro in a research note on Sunday. They issued a “hold” rating for the company. Truist Financial lowered their target price on shares of Nevro from $7.00 to $4.70 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Finally, Canaccord Genuity Group boosted their price target on Nevro from $4.00 to $5.85 and gave the stock a “hold” rating in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $6.43.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.